Impact of moderate- and high-intensity exercise on the endothelial ultrastructure and function in mesenteric arteries
1Department of Exercise Physiology, Beijing Sport University, Beijing 100084, China.
Abstract:
Oxidative stress (OS) influences vascular function and structure in spontaneously hypertensive rats (SHRs). It is also responsible for the decreased nitric oxide (NO) bioavailability that influences endothelial vasodilation. The effects of high-intensity exercise on endothelial function and ultrastructure in hypertension remain unknown. Thus, this study investigated the effects of moderate- and high-intensity exercise on hypertension-associated endothelial dysfunction and ultrastructural remodeling. Moderate-intensity (SHR-M) and high-intensity (SHRH) aerobic exercise training groups were compared in age-matched sedentary SHRs (SHRC) and normotensive Wistar-Kyoto rats (WKY-C). The results showed that the endothelial ultrastructure was impaired in the SHR-H and SHR-C groups. Glutathione peroxidase levels were significantly increased in the SHR-M group compared to the SHR-C group. MDA content was higher in the SHR-H group than in the SHR-C group, but the levels of antioxidant enzymes did not increase accordingly. Apocynin scavenging reactive oxygen species (ROS) ameliorated endothelium-dependent vasodilator function in the SHR-H group. However, the SHR-M and WKY-C groups abolished the increased vasodilation induced by apocynin. L-NAME, a NO synthase inhibitor, was applied to isolated mesenteric arteries (MAs) to evaluate NO contribution. Moderate-intensity exercise reversed the decreased NO contribution to MAs in hypertension, and high-intensity exercise aggravated this change. These data suggest that moderate-intensity exercise ameliorated adverse remodeling of the endothelial ultrastructure and function in hypertension by decreasing oxidative stress and increasing NO contribution. However, high-intensity exercise exacerbated all of these changes by increasing OS and ROS contribution, and decreasing NO contribution.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Sound Intensity
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...


